What question did this study set out to answer?

The study aims to assess the effect of glycoprotein IIb/IIIa receptor antagonists on clinical outcomes in ischemic heart disease.

December 22, 1998CirculationOpen Access

Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease

View Full Paper

Ask AI

Bookmark

Why the study?

Do platelet glycoprotein IIb/IIIa inhibitors reduce death, myocardial infarction, and revascularization in patients with ischemic heart disease?

Key Points

The study aims to assess the effect of glycoprotein IIb/IIIa receptor antagonists on clinical outcomes in ischemic heart disease.
Conducted a systematic overview (meta-analysis) of 16 randomized controlled trials
Included outcomes from 32,135 patients
Calculated odds ratios (ORs) for various endpoints including mortality and myocardial infarction
Significant reduction in mortality at 48 to 96 hours (OR 0.70, 95% CI 0.51 to 0.96, P<0.03)
30-day composite endpoint of death or MI improved (OR 0.76, 95% CI 0.66 to 0.87, P<0.001)
Composite outcome of death, MI, or revascularization also showed significant benefit (OR 0.77, 95% CI 0.68 to 0.86, P<0.001)

Structured PICO

Do platelet glycoprotein IIb/IIIa inhibitors reduce death, myocardial infarction, and revascularization in patients with ischemic heart disease?

Population

32,135 patients from 16 randomized controlled trials with ischemic heart disease (therapeutic indications: percutaneous intervention or acute coronary syndromes).

Intervention

Platelet glycoprotein (GP) IIb/IIIa inhibitors as a class

Comparator

Control group in randomized controlled trials

Outcome

Death, myocardial infarction (MI), and revascularization at 48 to 96 hours, 30 days, and 6 monthshard clinical

GP IIb/IIIa inhibitors significantly reduce the composite of death or MI, as well as death, MI, or revascularization, in patients with ischemic heart disease undergoing percutaneous intervention or presenting with acute coronary syndromes.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports GP IIb/IIIa inhibitor use in ACS and PCI; confirms composite benefit across trials.

Cite This Study

Kong et al. (1998) studied this question.

synapsesocial.com/papers/6a026eee7adabae4d9372a30 https://doi.org/10.1161/01.cir.98.25.2829

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider